anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
PURPOSE: To obtain the subject therapeutic agent comprising a combination of a thrombolytic agent with a perfluorochemical emulsion. CONSTITUTION: This therapeutic agent for myocardial infarction contains a thrombolytic agent as active ingredient in combination with a perfluorochemical emulsion; or contains a perfluorochemical emulsion as active ingredient in combination with a thrombolytic agent. The thrombolytic agent pref. contains at least one among tissue plasminogen activating factor, streptokinase, prourokinase, anistleplase and urokinase. The perfluorochemical emulsion is prepared from a base emulsion comprising a perfluorodecalin, perfluorotri-n- propylamine, poloxamer, yolk phospholipid, potassium oleate, glycerol and water.  Intravenous administration of this agent at a specified dose remedies ventricular function, remedying/mitigating a series of ischemic symptoms, i.e., venticular arrhythmia, non-reopening phenomena, capillary disorders, leukocytic embolism in interstitial edematous microcirculation, free radical formation, calcium mobilization, etc.
To overcome the potential drawback of the durable polymer a new generation of drug-eluting stent (DES) with a biodegradable polymer has been designed. The first-generation sirolimus-eluting or paclitaxel-eluting stents have a polymer release of antiproliferative drugs from a stainless steel stent platform. More recently, second generation DES have been developed not only to improve long-term DES safety but also to facilitate the procedure by using a cobalt-chromium (Co-Cr) stent platform. Co-Cr is stronger and more radiopaque than stainless steel, and thus allows strut thickness and total stent volume to be reduced while maintaining radial strength leading to a more flexible and deliverable stent platform.

The Sahajanand Medical Technologies Pvt. Ltd. (SMT) has developed sirolimus-eluting stent that contain a biodegradable polymer coating and a Co-Cr stent platform. The purpose of this registry is to evaluate the Supraflex Family sirolimus-eluting stent in a 'real-world' patient population, in order to determine the safety and efficacy of the stent in wider usage.
The active agents is racemic methylphenidate hydrochloride, modified release, a mild central nervous system stimulant (pharmacotherapeutic group: psychostimulants). Study medication will be taken once daily. Initially patients will be provided with 20mg and 30mg capsules of study medication. They are instructed to take 20mg within the first week and within the second week 30mg capsules. Visit 2 is scheduled two weeks after baseline and at Visit 2 patients will be provided with 40mg capsules and instructed to take them for the rest of the study.
PURPOSE: To improve a blood platelet yield of a separation device by supplying buffy coat among blood components centrifugally separated in a blood storing space to a buffy coat container, discharging the other components from the blood storing space to be transferred, returning buffy coat to the blood storing space, and performing centrifugal separation again for recovering blood plateles. CONSTITUTION: Blood in a blood bag 104 is introduced into a rotor 42 in a centrifugal bowl 4 through tubes 101, 103 to be centrifugally separated into plural blood components and collected in a blood storing space. A separated blood plasma layer is recovered from an upper part of the storing space to a blood plasma bag 21. Buffy coat is recovered from an outflow port 44 into a buffy coat bag 25. Next, a pump is inversely rotated to return red bood corpuscles left in the centrifugal bowl 4 into the blood bag 104. Buffy coat in the buffy coat 25 is then returned to the blood storing space, and it is processed with blood in the blood bag 104.
This project investigates if third-generation genomic sequencing can be used to identify the species of bacteria causing prosthetic joint infections (PJIs) at the time of revision surgery. Samples of prosthetic fluid were taken during revision surgery from patients with known PJIs. Samples from revision surgeries from non-infected patients acted as negative controls. Genomic sequencing was performed using the MinION device and the rapid sequencing kit from Oxford Nanopore Technologies. Bioinformatic analysis pipelines to identify bacteria included Basic Local Alignment Search Tool, Kraken2 and MinION Detection Software, and the results were compared with standard of care microbiological cultures. Furthermore, there was an attempt to predict antibiotic resistance using computational tools including ResFinder, AMRFinderPlus and Comprehensive Antibiotic Resistance Database. Bacteria identified using microbiological cultures were successfully identified using bioinformatic analysis pipelines. Nanopore sequencing and genomic classification could be completed in the time it takes to perform joint revision surgery (2-3 h). Genomic sequencing in this study was not able to predict antibiotic resistance in this time frame, this is thought to be due to a short-read length and low read depth. It can be concluded that genomic sequencing can be useful to identify bacterial species in infected joint replacements. However, further work is required to investigate if it can be used to predict antibiotic resistance within clinically relevant timeframes.
A method for producing microcapsules with a sun protection effect includes mixing tetraethoxysilane (TEOS), ethanol, and water and uniformly vibrating the mixture of TEOS, ethanol, and water. The TEOS, ethanol, and water have an appropriate ratio therebetween. Nitric acid is used to adjust the mixture of TEOS, ethanol, and water to have an appropriate pH value. The mixture is placed still to hydrolyze the mixture. The hydrolyzed mixture is heated and stirred to obtain a TEOS sol. Then, the TEOS sol, Span 80, and mineral oil are mixed in an approximate ratio to obtain a microemulsified TEOS gel. The microemulsified TEOS gel is centrifuged. The upper oil phase is removed. The lower water phase and powders are sucked, filtered, and cleaned. The powders are recycled and baked.
Progress in effective local therapy of prostate cancer has been stymied by the lack of an imaging technique capable of reliably identifying the location of cancer within the prostate. Magnetic Resonance Imaging is a promising candidate for imaging the prostate because of its high soft tissue contrast, multiplanar capabilities, and the potential for providing unique biologic information not available with other modalities. In addition to conventional T2-weighted imaging MRI techniques that provide unique biologic information include MR spectroscopy, diffusion weighted MRI, dynamic enhanced MRI and hypoxia imaging. All have shown promise in imaging tumors at a magnetic field strength of 1.5 Tesla but all have been limited by sensitivity. Since MR signal is proportional to magnetic field strength, 3.0 Tesla clinical systems potentially could improve overall diagnostic accuracy. A comprehensive imaging package which incorporates all these techniques to study prostate cancer on a state-of-the-art 3.0 Tesla magnet has not yet been developed.

In this pilot study we seek to develop and evaluate a comprehensive prostate MR exam at 3.0 Tesla. Patients with biopsy proven prostate cancer will undergo an MRI with endorectal and surface phased array coils which will include conventional sequences, MR spectroscopy, Diffusion weighted MRI, Dynamic enhanced MR and Hypoxia imaging. In the development phase of this trial (30 patients), the robustness of the techniques and test-retest reproducibility will be evaluated. In the second phase, the comprehensive prostate MRI exam will be validated against the results of prostate biopsy (50 patients). The expected accrual period is two years. We hope that this method will offer prostate cancer patients a more accurate method of localizing their prostate cancer than is now possible which should improve outcomes and minimize complications of treatment.
Dysport was injected into either one or both lower limbs in up to 4 cycles of treatment, a minimum of 12 weeks apart and up to a maximum of 40 weeks apart. Doses varied from 5 Units (U)/Kg to 20 U/kg for one leg, or from 10 U/Kg to 30 U/kg for two legs, with a maximum dose of no more than 30 U/Kg overall, or 1000 U, whichever was reached first.
Thyroid disorders affect more women than men, but the underlying mechanisms contributing to this disparity remain incompletely understood. Thyrotropin (TSH), the primary regulator of thyroid oxidative hormonogenesis, has been implicated as a risk factor for proliferative thyroid diseases and a predictor of malignancy. In this study, we aimed to evaluate the impact of sustained elevated TSH levels on thyroid redox homeostasis, inflammatory markers, and DNA damage response in both male and female rats. Rats were treated with methimazole for 7 or 21 days, and hormonal measurements were conducted. H2O2 levels were evaluated in thyroid membrane fractions, while enzymatic activities were assessed in total thyroid homogenates. Sex-specific differences emerged, with females displaying higher reactive oxygen species levels - increased transiently NOX and sustained DUOX activities. Lipid peroxidation marker 4-hydroxynonenal (4-HNE) was elevated in females at both time points, contrasting with males just at 21 days. Sexual dimorphism was observed in DNA damage response, with females showing higher γH2AX levels at 21 days. Elevated IL-1β, TNF-α, CD11b mRNA, and phospho-NF-κB levels at 7 days indicated a distinct inflammatory profile in females. Notably, both sexes exhibited upregulated antioxidant enzymes. Our data suggest that females are more susceptible to oxidative damage and inflammation in our goiter model, which may be associated with higher ROS production and a less-efficient antioxidant defense system. These findings provide insights into the sex-specific mechanisms underlying thyroid dysfunction and highlight the importance of considering sex disparities in thyroid disorder research.
OBJECTIVES: The aim of the study is to assess the efficacy of the established computed tomography (CT)-based radiomics nomogram combined with radiomics and clinical features for predicting muscle invasion status in bladder cancer (BCa).
METHODS: A retrospective analysis was conducted using data from patients who underwent CT urography at our institution between May 2018 and April 2023 with urothelial carcinoma of the bladder confirmed by postoperative histology. There were 196 patients enrolled in all, and each was randomized at random to either the training cohort (n = 137) or the test cohort (n = 59). Eight hundred fifty-one radiomics features in all were retrieved. For feature selection, the significance test and least absolute shrinkage and selection operator (LASSO) approaches were utilized. Subsequently, the radiomics score (Radscore) was obtained by applying linear weighting based on the selected features. The clinical and radiomics model, as well as radiomics-clinical nomogram were all established using logistic regression. Three models were evaluated using analysis of the receiver operating characteristic curve. An area under the curve (AUC) and 95% confidence intervals (CI) as well as specificity, sensitivity, accuracy, negative predictive value, and positive predictive value were included in the analysis. Radiomics-clinical nomogram's performance was assessed based on discrimination, calibration, and clinical utility.
RESULTS: After obtaining 851 radiomics features, 12 features were ultimately selected. Histopathological grading and tortuous blood vessels were included in the clinical model. The Radscore and clinical histopathology grading were among the final predictors in the unique nomogram. The three models had an AUC of 0.811 (95% CI, 0.742-0.880), 0.845 (95% CI, 0.781-0.908), and 0.896 (95% CI, 0.846-0.947) in the training cohort and in the test cohort they were 0.808 (95% CI, 0.703-0.913), 0.847 (95% CI, 0.739-0.954), and 0.887 (95% CI, 0.803-0.971). According to the DeLong test, the radiomics-clinical nomogram's AUC in the training cohort substantially differed from that of the clinical model (AUC: 0.896 versus 0.845, p = 0.015) and the radiomics model (AUC: 0.896 versus 0.811, p = 0.002). The Delong test in the test cohort revealed no significant difference among the three models.
CONCLUSIONS: CT-based radiomics-clinical nomogram can be a useful tool for quantitatively predicting the status of muscle invasion in BCa.
Patients receive ponatinib hydrochloride PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
Diabetes is a significant cause of cardiovascular and cerebrovascular events. Especially, diabetic patients with cardiovascular risk factors were significantly higher risk for cardiovascular and cerebrovasculara event. Therefore, several medical management strategies including anti-diabetic medications and statins were considered for those patients. However, in spite of such treatment, still many patients have cardiovascular and cerebrovascular events. One of the hypothesis is the residual risk such as elevated low-density lipoprotein cholesterol (LDLC) even with statin therapy. Anagliptin, one of the dipeptidyl peptidase-4 (DPP4) inhibiors, was reported to reduce LDLC and may have pontential to decrease the cardiovascular and cerebrovascular risk for such patients on statins. We, thus, conduct a randomized controlled trial to compare Anagliptin or Sitagliptin in terms of change of LDLC for 52 weeks as well as glycemic control.
Patients with a score like or above 25 on Post traumatic stress scale-10 Intensive Care Screen after discharge from the ICU. Nurse led follow up talks at the ward and one and two months later.
1. A method of treatment of nonconstipated female IBS which comprises administering an effective amount of a 5-HT3 receptor antagonist or a pharmaceutically acceptable derivative thereof selected from the group consisting of alosetron, granisetron, azasetron, tropisetron, ramosetron, ondansetron, lerisetron, (R) zacopride, cilansetron, itasetron, indisetron and dolasetron and pharmaceutically acceptable derivatives thereof. 2. A method according to claim 1, wherein the 5-HT3 receptor antagonist a pharmaceutically acceptable derivative is alosetron or a pharmaceutically acceptable derivative thereof. 3. A method according to claim 2 wherein alosetron is in the form of its hydrochloride. 4. A method of treatment of alternating constipation/diarrhea which comprises administering an effective amount of a 5-HT3 receptor antagonist or a pharmaceutically acceptable derivative thereof selected from the group consisting of alosetron, granisetron, azasetron, tropisetron, ramosetron, ondansetron, lerisetron, (R) zacopride, cilansetron, itasetron, indisetron and dolasetron and pharmaceutically acceptable derivatives thereof. 5. A method according to claim 4, wherein the 5-HT3 receptor antagonist a pharmaceutically acceptable derivative is alosetron or a pharmaceutically acceptable derivative thereof. 6. A method according to claim 5, wherein alosetron is in the form of its hydrochloride. 7. A method according to claim 1 or 4, wherein said nonconstipated female IBS is the nonconstipated female IBS of diarrhea-predominant female IBS. 8. A method according to claim 7, wherein the 5-HT3 receptor antagonist a pharmaceutically acceptable derivative is alosetron or a pharmaceutically acceptable derivative thereof. 9. A method of treatment according to claim 8, wherein alosetron is in the form of its hydrochloride.
The invention discloses an application of a nucleic acid aptamer in preparing a medicament for treating Alzheimer's disease. The aptamer Ob2 which is combined with human AChE is screened out by SELEX technology, and the nucleotide sequence of the nucleic acid aptamer Ob2 is shown as SEQ ID NO. 2. In vitro test, Ob2 has the effect of inhibiting AChE activity. Through lateral ventricle administration, Ob2 can improve spatial learning and memory ability of an Alzheimer Disease (AD) model mouse, and reduce the contents of Abeta 40 and Abeta 42 in hippocampal and cortical layers and the number of senile plaque deposits of the mouse. Due to the high specificity and high binding property of the aptamer, the aptamer aiming at human AChE is a powerful tool for detecting AChE in vitro and in vivo, and is expected to be developed into a novel AChE inhibitor for treating AD and other diseases. Provides a research foundation for the development of novel specific AChE inhibition and provides a new method and a new thought for AD treatment.
The Couples Arm intervention addressed gaps identified from baseline findings. It involved comprehensive family planning education delivered to married women and men by community agents, Health Extension Workers, and FP experts using flyers, booklets, and face-to-face discussions. Health Extension Workers supported community agents in delivering health education messages about family planning twice a month for 6 months, with each session lasting 2 hours. Note: The group size for the Couples Arm was 748 couples (374 women and 374 men).
According to the score obtained with the onco geriatric evaluation, patients with a score inferior to 119 will receive a large hypo fractionated radiotherapy (30 Grays in 5 weekly fractions). This scheme of radiotherapy is already used in the usual practice, but not allocated according to a score obtained at an oncogeriatric evaluation.
Study procedures include the Scar Cosmesis Assessment and Rating (SCAR) scale and numerical rating scale (NRS) questionnaire at one, 14 and 30 days after totally endoscopic coronary artery bypass grafting. Additionally, a photo of the incisions will be taken at these time points.
This study addresses the effects of blindness on trust. Using an auditory version of the multi-round Trust Game, we investigated the effect of reputation and reciprocity on trust decisions in early blind and sighted participants. During each round of the game, participants were endowed with a sum of money and had to decide how much they wanted to invest in their partners, who were manipulated as a function of their good or bad reputation and individualistic or cooperative behavior. The data showed that negative first impression about the partner (bad reputation and/or selfish behavior) impacted more blind participants than sighted ones. However, following repeated interactions with the partners, the overall mean investment aligned between the blind and sighted groups. We interpret these findings as suggesting that blindness may guide participants to a more cautionary behavior when dealing with partners with negative initial characteristics.
The etiology of hemobilia has mainly iatrogenic (>50%), followed by traumatic causes. Others are biliopathy due to portal high pressure, or neoplastic or infective biliopathy. In the case of non-clear hemobilia, direct-vision-cholangioscopy can change the management in >34% of cases. Our patient had episodes of obstructive hemobilia with secondary cholangitis without objectifying underlying pathology. When she was referred to our center, SpyGlass®-cholangioscopy identified the suspicious lesion compatible with early-stage cholangiocarcinoma despite the diagnostic delay. In conclusion, it is important to keep in mind the neoformative etiology as a potential cause of hemobilia of unclear origin, in which case, cholangioscopy (SpyGlass®) can contribute to the recognition of the signs of malignancy of the lesion and, therefore, to the diagnosis.
PROBLEM TO BE SOLVED: To provide a composition for oral cavity application effective for preventing the discoloration with time caused by ascorbic acid or its derivative. SOLUTION: A crystalline cellulose is compounded to an oral cavity composition containing one or more components selected from ascorbic acid and its derivative. The crystalline cellulose to be used in the present invention means an agglomerate of cellulose crystallites having essentially uniform degree of polymerization and produced by the acid hydrolysis or alkali hydrolysis of α-cellulose obtained from a fibrous vegetable in the form of pulp. The average particle diameter of the crystalline cellulose is preferably 50-200 μm in dry state. Sufficient cleaning power cannot be attained when the diameter is smaller than 50 μm and abnormal feeling is sometimes generated in use to deteriorate the feeling when the diameter is larger than 200 μm. More preferable mean particle diameter is 70-150 μm.
A system for facilitating monitoring of fitness devices is disclosed. The system may include a plurality of sensors configured to be attached to a plurality of fitness devices. Further, the system may include a plurality of transceivers communicatively coupled with the plurality of sensors. Further, the system may include a plurality of local processing devices communicatively coupled to each of the plurality of sensors and the plurality of transceivers. Further, the system may include a server computer. The server computer may include a server communication device configured for communicating with the at least one transceiver. Further, the server computer may include a server processing device communicatively coupled with the server communication device. Further, the server processing device may be configured for analyzing the sensor data and generating at least one insight. Further, the server computer may include a server storage device communicatively coupled to the server processing device.
A-40104 antibiotic complex, comprising active factors A, B, C, and D, produced by submerged aerobic fermentation of Clitopilus pseudo-pinsitus. Individual factors, A, B, and C have been isolated. A-40104 factor C is the known antibiotic pleuromutilin. A-40104 factors A and B are novel antibiotics related to pleuromutilin. A-40104 factor A, the major new factor, is the D-xylose acetal derivative of pleuromutilin. A-40104 factors A and B, their 19,20-dihydro derivatives and the per(C 2  -C 6 )alkanoyl derivatives of factors A and B and of their 19,20-dihydro derivatives are active against gram-positive and gram-negative bacteria, anaerobic bacteria, and Mycoplasma.